BR112023020152A2 - Inibidores terapêuticos de sinalização gdf15 - Google Patents

Inibidores terapêuticos de sinalização gdf15

Info

Publication number
BR112023020152A2
BR112023020152A2 BR112023020152A BR112023020152A BR112023020152A2 BR 112023020152 A2 BR112023020152 A2 BR 112023020152A2 BR 112023020152 A BR112023020152 A BR 112023020152A BR 112023020152 A BR112023020152 A BR 112023020152A BR 112023020152 A2 BR112023020152 A2 BR 112023020152A2
Authority
BR
Brazil
Prior art keywords
gdf15
signaling
gfral
therapeutic inhibitors
relates
Prior art date
Application number
BR112023020152A
Other languages
English (en)
Portuguese (pt)
Inventor
Adam Carpenter
Patrick Coll Anthony
E-Chiang Lee
Hui Liu
Irene Cimino
Stephen O?Rahilly
Original Assignee
Cambridge Entpr Ltd
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed by Cambridge Entpr Ltd, Kymab Ltd filed Critical Cambridge Entpr Ltd
Publication of BR112023020152A2 publication Critical patent/BR112023020152A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112023020152A 2021-03-31 2022-03-31 Inibidores terapêuticos de sinalização gdf15 BR112023020152A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (1)

Publication Number Publication Date
BR112023020152A2 true BR112023020152A2 (pt) 2023-11-14

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020152A BR112023020152A2 (pt) 2021-03-31 2022-03-31 Inibidores terapêuticos de sinalização gdf15

Country Status (11)

Country Link
US (1) US20240182585A1 (enExample)
EP (1) EP4314071A1 (enExample)
JP (1) JP2024511853A (enExample)
KR (1) KR20230165285A (enExample)
AU (1) AU2022251923A1 (enExample)
BR (1) BR112023020152A2 (enExample)
CA (1) CA3215737A1 (enExample)
CO (1) CO2023013791A2 (enExample)
IL (1) IL307382A (enExample)
MX (1) MX2023011655A (enExample)
WO (1) WO2022207846A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
ES2518865T3 (es) 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2783934A1 (en) 2009-12-11 2011-06-16 Genecode As Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
PT2900263T (pt) 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15)
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP3122775B1 (en) 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
JP6925326B2 (ja) 2015-10-02 2021-08-25 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
AU2017228489A1 (en) 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途

Also Published As

Publication number Publication date
WO2022207846A1 (en) 2022-10-06
EP4314071A1 (en) 2024-02-07
CO2023013791A2 (es) 2024-01-25
MX2023011655A (es) 2023-10-11
IL307382A (en) 2023-11-01
KR20230165285A (ko) 2023-12-05
JP2024511853A (ja) 2024-03-15
CA3215737A1 (en) 2022-10-06
US20240182585A1 (en) 2024-06-06
AU2022251923A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
Wang et al. Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors
Mayahara et al. Osteoblasts stimulate osteoclastogenesis via RANKL expression more strongly than periodontal ligament cells do in response to PGE2
Sarris et al. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression
Tsubaki et al. Bisphosphonate-and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2
Lee et al. AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells
Yang et al. ER-stress regulates macrophage polarization through pancreatic EIF-2alpha kinase
BR112021015238A8 (pt) Novos anticorpos de ligação a cd40
Morgese et al. Lifelong nutritional omega-3 deficiency evokes depressive-like state through soluble beta amyloid
Mukhuty et al. Palmitate induced Fetuin-A secretion from pancreatic β-cells adversely affects its function and elicits inflammation
BR112013000446A2 (pt) composição nutricional para a estimulação de síntese de proteína muscular
Kim et al. Effects of glutamine on proliferation, migration, and differentiation of human dental pulp cells
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
Wang et al. Sparstolonin B inhibits lipopolysaccharide-induced inflammation in 3T3-L1 adipocytes
BR112022012324A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
Hisaoka-Nakashima et al. Mirtazapine increases glial cell line-derived neurotrophic factor production through lysophosphatidic acid 1 receptor-mediated extracellular signal-regulated kinase signaling in astrocytes
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
BR112017023158A2 (pt) anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
Suzuki et al. ChREBP binding and histone modifications modulate hepatic expression of the Fasn gene in a metabolic syndrome rat model
Hioki et al. Olive polyphenols attenuate TNF-α-stimulated M-CSF and IL-6 synthesis in osteoblasts: Suppression of Akt and p44/p42 MAP kinase signaling pathways
CO2023013791A2 (es) Inhibidores terapéuticos de la señalización de gdf15
Thandapilly et al. Canola oil rich in oleic acid improves diastolic heart function in diet-induced obese rats
Panaroni et al. Arachidonic acid induces ferroptosis-mediated cell-death in multiple myeloma
BR112021021015A2 (pt) Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais
Wang et al. Anti-inflammation effects of naloxone involve phosphoinositide 3-kinase delta and gamma
Belegri et al. The effects of overnight nutrient intake on hypothalamic inflammation in a free-choice diet-induced obesity rat model